Results 261 to 270 of about 18,808,658 (397)

Controlled Release of Human Dental Pulp Stem Cell‐Derived Exosomes from Hydrogels Attenuates Temporomandibular Joint Osteoarthritis

open access: yesAdvanced Healthcare Materials, EarlyView.
Exosomes can reduce tissue damage in temporomandibular joint osteoarthritis (TMJOA), but rapid clearance limits their efficacy. This study encapsulates exosomes in hyaluronic acid hydrogels for controlled release. In a rat model, hydrogel‐encapsulated exosomes outperform free exosomes in preserving bone integrity and reducing tissue destruction ...
Victor Diez‐Guardia   +7 more
wiley   +1 more source

Interventions to improve patient safety during the COVID-19 pandemic: a systematic review. [PDF]

open access: yesBMJ Open Qual
Wu AW   +14 more
europepmc   +1 more source

Kidney Stone Dissolution By Tetherless, Enzyme‐Loaded, Soft Magnetic Miniature Robots

open access: yesAdvanced Healthcare Materials, EarlyView.
Wireless magnetic robots are developed for kidney stone dissolution. The robots navigate through a urinary tract model from bladder and ureter to renal pelvis with the help of external magnetic fields. The filaments are loaded with urease enzyme which catalyzes urea to carbon dioxide and ammonia, thereby increasing pH to basic regime and supporting ...
Afarin Khabbazian   +15 more
wiley   +1 more source

Economic case for reducing inequities in patient safety. [PDF]

open access: yesBMJ Open Qual
Munford LA   +3 more
europepmc   +1 more source

"The Safety and Efficacy of A Two-Dose Daclizumab (Zenapax) Induction Therapy In Liver Transplant Patients"

open access: bronze, 1999
Devin E. Eckhoff   +7 more
openalex   +1 more source

Reservoir‐Type Subcutaneous Implantable Devices Containing Porous Rate Controlling Membranes for Sustained Delivery of Risperidone

open access: yesAdvanced Healthcare Materials, EarlyView.
This study presents a novel implantable drug delivery systemwith a biodegradable poly(caprolactone) membrane and compressed drug core forsustained release. These implantable devices deliver risperidone in vitro for 170 days and in vivo for 49 days in rats, showing promise for chronic conditions like schizophrenia.
Linlin Li   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy